FOR US HEALTHCARE PROFESSIONALS

For the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

Ready to get a patient started on AURYXIA?

Learn about dosing and titration.

AURYXIA is uniquely formulated for your patients:

  • An iron-based, non-calcium tablet1
  • Film-coated tablet that is swallowed, not chewed or crushed1
  • No discoloration of the mouth when swallowed whole1

Dosing guidelines1

Artistic representation icon of a fork, knife and dish

AURYXIA is taken
with meals

Artistic representation of two capsules and the number three

Starting dose 2 tablets
3 times/day

Artistic representation of a calendar

Adjust dose every week (or longer) as needed

Artistic representation of a circle with the number twelve in the middle

Maximum dose
12 tablets daily

Titration guidelines

Artistic representation of two capsules with the plus and minus signs next to them

AURYXIA can be titrated in increments or decrements of 1 to 2 tablets per day to maintain serum phosphorus target levels1

Artistic representation of a calendar

Titrate AURYXIA at 1-week or longer intervals1

Oral drugs that cannot be taken at the same time as AURYXIA1

  • Doxycycline—Take at least 1 hour before AURYXIA
  • Ciprofloxacin—Take at least 2 hours before or after AURYXIA
  • For oral medications where a reduction in bioavailability would have a clinically significant effect, consider separation of timing of administration with AURYXIA

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

DRUG INTERACTIONS

When clinically significant drug interactions are expected, e.g., Ciprofloxacin or Doxycycline, separate timing of administration.

INDICATION

AURYXIA® (ferric citrate) is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCE

  1. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.